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Background: Sudden cardiac death occurs commonly in the end-stage renal disease population receiving dialysis,
with 25% dying of sudden cardiac death over 5 years. Despite this high risk, surprisingly few prospective studies
have studied clinical- and dialysis-related risk factors for sudden cardiac death and arrhythmic precursors of sudden
cardiac death in end-stage renal disease.
Methods/Design: We present a brief summary of the risk factors for arrhythmias and sudden cardiac death in
persons with end-stage renal disease as the rationale for the Predictors of Arrhythmic and Cardiovascular Risk in
End Stage Renal Disease (PACE) study, a prospective cohort study of patients recently initiated on chronic
hemodialysis, with the overall goal to understand arrhythmic and sudden cardiac death risk. Participants were screened
for eligibility and excluded if they already had a pacemaker or an automatic implantable cardioverter defibrillator. We de-
scribe the study aims, design, and data collection of 574 incident hemodialysis participants from the Baltimore region in
Maryland, U.S.A.. Participants were recruited from 27 hemodialysis units and underwent detailed clinical, dialysis and car-
diovascular evaluation at baseline and follow-up. Cardiovascular phenotyping was conducted on nondialysis days
with signal averaged electrocardiogram, echocardiogram, pulse wave velocity, ankle, brachial index, and cardiac
computed tomography and angiography conducted at baseline. Participants were followed annually with study visits
including electrocardiogram, pulse wave velocity, and ankle brachial index up to 4 years. A biorepository of serum,
plasma, DNA, RNA, and nails were collected to study genetic and serologic factors associated with disease.
Discussion: Studies of modifiable risk factors for sudden cardiac death will help set the stage for clinical trials to test
therapies to prevent sudden cardiac death in this high-risk population.
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Despite improvements in access to care, the dialysis pro-
cedure, and management of complications related to end-
stage renal disease (ESRD), mortality in ESRD remains
high [1]. Sudden cardiac deaths (SCD) are common
among dialysis patients with approximately 25% of deaths
in both observational studies and clinical trials [2]. Pub-
lished rates of SCD among the ESRD populations vary* Correspondence: rulan.parekh@sickkids.ca
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unless otherwise stated.greatly based on definitions used to define it [3]. In con-
trast to the general population, the incidence rate of
cardiac arrest as a surrogate of SCD in ESRD is almost
50 fold greater [4]. These rates of SCD among
hemodialysis patients approach similar rates in persons
who experienced myocardial infarction in the general
population. Despite this high-risk, few prospective studies
have been conducted to define the incidence and risk fac-
tors for SCD in ESRD. Moreover, therapy including im-
plantable defibrillators is controversial [5-7]. Herein, we
focused our discussion on the main goals of the Predictors
of Arrhythmic and Cardiovascular Risk in End Stage RenalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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related factors contributing to arrhythmias and SCD.
Assessment of arrhythmic risk
Key to the pathogenesis of arrhythmias and SCD is the
abnormal myocardium which is highly susceptible to ab-
normal ventricular conduction either spontaneously or via
additional triggers. There are a number of noninvasive
markers of myocardial vulnerability including electrocar-
diogram (ECG) changes at rest or from ischemia, and al-
terations in dynamic ECG parameters which can be used
to risk stratify persons at risk for sudden death and repre-
sent intermediate markers of SCD risk [8,9]. Some of these
ECG measures represent various mechanisms of develop-
ing life-threatening arrhythmias and include heart rate
variability (HRV), ventricular late potentials (VLP), and
QT interval prolongation.
HRV is defined as the variation in RR intervals and
serves as a surrogate marker of autonomic dysfunction
[10]. Alteration of the balance between sympathetic and
parasympathetic tone by disease states can lead to de-
pressed vagal tone and a resultant predominance of sym-
pathetic activity, leading to tachycardia and cardiac
electrical instability. In persons with chronic kidney dis-
ease, sympathetic hormone levels are 5 times greater
than healthy controls [11]. Arterial hypotension during
hemodialysis also leads to increased sympathetic activity.
Depending on the studies, there is a wide range of esti-
mated prevalence of abnormal HRV in dialysis from 16
to 76% [12-16]. Severe or moderately depressed HRV is
more common in those receiving hemodialysis than
those on peritoneal dialysis or the general population,
and may also be affected by diabetes and hemodialysis
treatments [12-21].
VLPs are low amplitude signals, in the microvolt
range, occurring in the last few milliseconds of the QRS
complex and extending into the ST segment. It is nor-
mally hidden by the much larger voltages of the QRS
and ST segments and can only be detected using signal
averaged ECG (SAECG) [22]. VLPs represent conduction
delay within the myocardium due to fibrosis, ischemia,
or other disease states. Previous studies have demon-
strated VLPs as highly specific predictors of both indu-
cible ventricular tachycardia in the general population
and SCD in persons having a myocardial infarction [23].
The prevalence of VLPs in hemodialysis patients ranges
from 7 to 25%, but does not consistently vary with dialy-
sis treatment or electrolyte changes [22,24-26].
The QT interval is measured from the first deflection of
the QRS complex to the end of the T wave and corrected
for the heart rate using any one of a number of corrections
[27]. A prolonged QT interval reflects delayed repolariza-
tion. Temporal variability of the repolarization can result in
electrical instability and ventricular arrhythmias [8,28], anda prolonged QT has been shown to be associated with a
higher incidence of SCD [27,29,30]. The QT interval is in-
fluenced by patterns of ventricular activation, heart rate,
and autonomic tone. Electrolyte imbalances and drugs are
also common causes of prolonged QTc. Prolonged QTc
greater than 0.44 ms is present in 3-87% of hemodialysis
patients prior to a dialysis treatment depending on popula-
tion and increases to 6-99% after hemodialysis [31-40]. The
QTc is longer in patients on hemodialysis than in those on
peritoneal dialysis, possibly related to lower serum potas-
sium and calcium levels [41]. Calcium primarily affects the
QT interval and may increase or decrease depending on
dialysis bath and dialysis treatments [36]. Elevated QT vari-
ability index has also been described in 47% of persons with
chronic kidney disease and is associated with diabetes and
baseline coronary artery disease [42].
Assessment of vulnerable myocardium
Left ventricular hypertrophy (LVH) and structural heart
disease are strongly associated with the development of
SCD in the general population [43,44]. Similarly, in the dia-
lysis population, greater left ventricular (LV) mass index is
an independent predictor of SCD [45]. LVH is present in
40 to 74% of patients with ESRD [46,47] and could reduce
coronary blood flow and increase oxygen consumption of
the myocardium. This imbalance in coronary blood flow
and myocardial oxygen requirement can subsequently lead
to ischemia, prolongation of the QTc interval, and arrhyth-
mias [39,48-51]. Worsening LVH is also associated with
new onset heart failure [52], which occurs in 7% of the
ESRD population annually [4,53]. Though traditional base-
line risk factors for atherosclerotic cardiovascular disease
are associated with a higher risk of SCD, additional mea-
sures of subclinical cardiomyopathy and cardiovascular dis-
ease that are more common in dialysis patients, such as
coronary and vascular calcification, and vascular stiffness,
need to be studied with respect to arrhythmic risk [54].
Dialysis-related risk factors associated with SCD and
arrhythmias
With the typical conventional regimen of thrice weekly
hemodialysis, patients are subjected to a particularly un-
physiological state that includes elevated serum potassium
and magnesium before dialysis and low after dialysis, low
calcium or high calcium-phosphorus product, acidosis,
hypertension, and fluid overload. All of these conditions
have been associated with lethal arrhythmias and SCD in
the general population, especially in those with prevalent
cardiovascular disease [55-58]. Hemodialysis is not admin-
istered for 2 consecutive days each week, resulting in even
more significant fluid gain, hypertension and elevated po-
tassium. Mortality among hemodialysis patients is also
more frequent on Mondays and Tuesdays after the 2 days
off dialysis suggesting that, indeed, the unphysiologic milieu
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cardiac arrest is also more common on Mondays and more
likely when the patient is dialyzed against a 0 or 1.0 mEq/L
potassium dialysate (17.1 vs. 8.8%) [60].
Arrhythmias can occur at initiation of dialysis and also
toward the end of the dialysis session, probably due to fluc-
tuations in electrolytes and fluid [11]. Exaggerated sympa-
thetic responses also occur at higher rates of ultrafiltration
[17]. Concentrations of potassium and calcium, important
in regulation of electrical conduction in the heart, are ad-
justed in the dialysis solution (or dialysis bath) on an indi-
vidual patient basis, perhaps increasing the arrhythmic risk
[60]. Low calcium dialysate is now commonly used because
of increasing total body calcium burden in ESRD. A recent
study has demonstrated the relationship between lower cal-
cium dialysate and higher SCD relationship between using
a case- control design and requires further confirmation
[61].
Additional factors during dialysis therapy such as
hypotension and increased ultrafiltration lead to dimin-
ished coronary and cerebral perfusion which, in turn,
promotes arrhythmias. Such episodes of hypotension
are independently associated with in-unit cardiac arrest
[60]. In persons with intradialytic hypotension, auto-
nomic control of the heart is impaired [18] and typically
associated with impaired LV diastolic function [18,62].
Prospective studies are needed to assess the relative roles
of intradialytic hypotension and ventricular function, and
the risk for arrhythmias and SCD. To that end, the Pre-
dictors of Arrhythmic and Cardiovascular Risk in End
Stage Renal Disease study was initiated.
Methods
Study design of the predictors of arrhythmic and
cardiovascular risk in end stage renal disease (PACE) study
The overall objective of the study was to determine risk
factors (cardiovascular, dialysis-related, environmental and
genetic) associated with disordered cardiac autonomic
regulation and ventricular conduction, as well as with inci-
dence of SCD, in ESRD patients treated with hemodialysis.
The study was organized around the following aims and
followed the conceptual model based on the understanding
of risk factors leading to SCD (Figure 1).
Aim 1: Establish a cohort of incident hemodialysis
patients and describe the incidence of SCD
Aim 2. Determine the association of putative risk
factors with disordered cardiac autonomic
regulation and ventricular conduction in both
cross-sectional and prospective analyses
Aim 3. Determine the association of disordered cardiac
autonomic regulation and ventricular conduction
and other putative risk factors with incidence of
SCD over follow-up.Study overview and inclusion criteria
This prospective cohort study recruited persons with inci-
dent ESRD in Baltimore and the surrounding area from 25
free-standing outpatient dialysis units (DaVita and Med-
star) and 2 hospital-based outpatient units (MedStar).
Incident dialysis was defined as less than 6 months on
regular outpatient thrice weekly hemodialysis.
The participants were screened in the dialysis unit to
determine eligibility and, if eligible, were consented.
The inclusion criteria for participation were as follows:
(1) incident hemodialysis therapy defined as starting
within the 6 months before enrollment; (2) signed in-
formed consent; (3) age 18 years or older; (4) English
speaking; and (5) ability to tolerate the imaging and ECG
procedures and complete questionnaires. The criteria for
exclusion were as follows: (1) home hemodialysis or peri-
toneal dialysis patients; (2) patients in hospice or skilled
nursing facility or prison; (3) persons with cancer other
than nonmelanoma skin cancer; (4) presence of a pace-
maker; (5) presence of an automatic implantable cardio-
verter defibrillator; (6) pregnant or nursing mothers
(pregnancy test done prior to imaging); and (7) health
conditions that interfere with study participation (such as
substance abuse, dementia, or psychotic illness).
The consented participants were interviewed in the
dialysis unit and brought to the Johns Hopkins Insti-
tute for Clinical and Translational Research (ICTR)
clinic located at Johns Hopkins Hospital for a clinic
visit on a nondialysis day. These dialysis unit and
clinic visits were performed annually for up to 4 years.
Participants were also followed semi-annually with
a phone call to assess recent hospitalizations. In
addition, at every 4- and 8-month interval, the partici-
pants were called by trained dieticians to reassess their
dietary 24-hour recall. Lastly, every 6 months, the
coordinators contacted the clinic to determine dialy-
sis discontinuation, hospitalizations, and vital status
information.
Study procedures
Briefly, we conducted detailed questionnaires in the
dialysis unit and at the clinic visits at baseline and at
annual study visits (see Table 1 for schedule and ques-
tionnaires). Detailed questions on socio-demographic
information, education, employment, family history,
medications, medical history, female reproductive his-
tory, quality of life, recreational drug use, depressive
symptoms, cognitive function, frailty, physical activity,
dietary history, smoking, alcohol history, and trans-
plant evaluation were included.
For the clinic visits, participants came to the Johns
Hopkins ICTR clinic for a physical examination, cardiac
evaluation, cognitive testing, and frailty assessment. All
participants were instructed to fast for at least 8 hours
Figure 1 Conceptual model of the predictors of arrhythmic and cardiovascular risk in end stage renal disease (PACE) study.
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done at the earliest appointment in the morning, and
participants were encouraged to not engage in activity as
they were fasting prior to the visit. All study evaluations
were conducted on nondialysis days to ensure uniformity
across the study population. The visits included a physical
examination (anthropometry and waist to hip ratio), three
resting blood pressures using an oscillometric machine,
frailty assessment (grip strength and timed walking meas-
urement), and cardiovascular assessments (four-limb
blood pressure, if indicated, for ankle brachial index, pulse
wave analysis and velocity, standard 12-lead ECG, and two
5- and 2-minute digital signal averaged ECG recordings).
Participants were asked to bring in their medications and
all outpatient medications were recorded. Additionally,
computed tomography [CT] scan for coronary and valvu-
lar calcium and angiography (if not contraindicated), and
echocardiogram were conducted at baseline only. Bio-
logical specimens were collected at the time of each study
visit for the biorepository. Measurement of ionized cal-
cium and serum magnesium were done at each study visit.Baseline and annual data collection
Data collected from questionnaires have primarily
used standardized, validated, and reliable question-
naires similar to the Chronic Renal Insufficiency Co-
hort (CRIC) Study [63,64]. Race was self-reported.
Physical activity was determined using the Minne-
sota Activity Index [65]. Dietary intake data using
the 24-hour food frequency questionnaire/assessment
were collected and analyzed using Nutrition Data
System for Research software versions 2009–2013
developed by the Nutrition Coordinating Center
(NCC), University of Minnesota, Minneapolis, MN.
The Nutrition Data System for Research provides a
complete nutrient profile for all foods in the
database.
Additional data prior to or at dialysis initiation were
collected from medical records and the Center for
Medicaid and Medicare Services (CMS) form-2728.
Electronic dialysis records for all treatments during the
study period for all participants were also provided by
the dialysis providers, DaVita and MedStar, with. These
Table 1 Schedule of measurements and activities by visit for the PACE study
Baseline visit Follow-up (FU) Visits and Telephone (T) Contacts
EV BV T4 T6 T8 FU12 T16 T18 T20 FU24 Up to FU48
Interviewer/Questionnaires§
Informed consent ●
Contact information ● ● ● ● ● ●
Sociodemographic ●
Education and employment ● ● ● ●
Vascular access ● ● ● ●
Residual kidney function ● ● ● ●
Dialysis prescription ● ● ● ●
Dialysis adherence ● ● ● ●
Pre-dialysis education ● ● ● ●
Medical history ● ● ● ● ● ●
Family history of CVD, SCD ●
Female reproductive history ● ● ● ●
Health, behaviour, social history ● ● ● ●
Access to transplant ● ● ● ●
KDQOL-36 ● ● ● ●
Symptomatic CVD (Rose, KCQ) ● ● ● ●
Physical activity ● ● ● ●
Dietary questions & 24-hr recall ● ● ● ● ● ● ● ●
Literacy (WRAT4) ●
Cognition (Trails A&B, 3MS) ● ● ● ●
Depression (PHQ9) ● ● ● ●
Oral medications ● ● ● ●
Examination
Height, weight, BMI, WHR ● ● ● ●
Blood pressures ● ● ● ●
Detailed amputation evaluation ● ● ● ●
Frailty assessment ● ● ● ●
Procedures
CT calcium and angiography ●
Echocardiography ●
Pulse wave velocity ● ● ● ●
12 lead & signal averaged ECG ● ● ● ●
4 Limb ankle brachial ● ● ● ●
Blood tests (fasting)
Ionized calcium, magnesium ● ● ● ●
Repository (DNA, RNA, blood, nails) ● ● ● ●
Clinical
Baseline charlson co-morbidity ●
CMS-2728 medical evidence ●
Hospitalizations Throughout the entire study period
CMS-2746 death notification‡ Collect as needed
Parekh et al. BMC Nephrology  (2015) 16:63 Page 5 of 14
Table 1 Schedule of measurements and activities by visit for the PACE study (Continued)
Dialysis routine bloods (monthly) Throughout the entire study period
Glucose, albumin
Complete blood count
Electrolytes (Na, K, Mg, CO2, Ca, Phos)*
Intact PTH*
Fe, TIBC, Ferritin, Aluminum*
URR, spKt/V, nPCR*
Dialysis treatments (weekly)‡‡ Throughout the entire study period
Dry weight
Dialysis bath (Ca, K, HCO3)*
Prescription (duration, frequency, dialyzer)
Pre and post weights




§KCQ = Kansas City Questionnaire; KDQOL-36 = Kidney Disease Quality of Life 36 Item Instrument; WRAT4 =Wide Range Achievement Test 4th Edition; Trails
A&B; 3MS =Modified Mini-Mental Status Exam; PHQ9 = Patient Health Questionnaire 9; ¶BMI = Body Mass Index; WHR =Waist Hip Ratio; Blood Pressure is collected
as 3 seated Blood Pressures; ‡Collected as needed; *Na- sodium K- potassium; Ca- calcium; Phos- phosphorus; HCO3- bicarbonate; PTH- parathyroid hormone level;
Fe- iron; TIBC- total iron binding capacity; URR- urea reduction ratio; nPCR- nitrogen protein catabolic rate; ‡‡Dialysis Machine Derived Parameters: BP-pre, BP-post, Lowest BP,
Weight-pre, Weight-post, Intradialytic Weight Gain, & Average Blood Flow Rate.
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dialysis prescription values.
Cardiovascular evaluation
Electrocardiogram (ECG) recording and analysis
We conducted ECG recording at baseline and annual
follow-up visits. We defined specific ECG parameters in
Table 2. A standard 12-lead ECG was recorded at rest in
supine position using the Marquette MAC 5500 HD
ECG system (GE Medical Systems, Milwaukee, WI).
High resolution (1000 Hz). Orthogonal Frank XYZ ECG
was recorded using the Norav 1200 M PC ECG machine
(Norav Medical Ltd, Thornhill, ON, Canada) at rest in
the supine position for at least 5 minutes. Only sinus
beats were included in the analysis. Subjects with serious
cardiac arrhythmias defined as ventricular tachycardia,
ventricular fibrillation, and atrial fibrillation/flutter were
captured, if detected, based on standard criteria [9].
Atrial fibrillation/flutter, as well as premature atrial and
ventricular contractions with the first subsequent beat were
excluded from subsequent analyses. Fiducial points were
automatically detected on each ECG lead and verified by
investigators as previously described [66]. Bazett (QTB)
[67], Fridericia (QTF) [68], and individualized (QTi) [69] ap-
proaches for QT correction were applied. Both time do-
main and frequency domain HRV analyses were performed
as recommended by the European Society of Cardiology/
North American Society of Pacing and Electrophysiology(ESC/NASPE) Task Force, as well as the American College
of Cardiology (ACC)/ American Heart Association (AHA)
guidelines for analysis of short-term recordings [9]. Robust
automated template matching techniques were used for
QT variability analyses [70,71].
Additionally, SAECG was obtained with a MAC 5500
HD ECG system (GE Medical Systems, Milwaukee, WI),
with bandpass filtering of 40–250 Hz, and averaging of
350 QRS complexes. The following SAECG characteristics
of the filtered QRS were evaluated [72,73]: (1) total dur-
ation (fQRSd), (2) duration of the low-amplitude signals
(<40 mV) in the terminal portion (LAS40), and (3) root-
mean-square voltage of the last 40 ms (RMS40). VLPs
were considered positive when ≥2 of the following criteria
were fulfilled: (1) fQRSd >114 ms, (2) LAS40 > 38 ms, and
(3) RMS40 < 20 μV.
All ECG measures are analyzed as continuous variables
or clinical categories based on standardized methods
[9,55], and are studied as potential effect modifiers [74].
Subclinical measures of myocardial substrate
All subclinical CVD measures used standardized protocols
similar to the CRIC Study (Table 2) [63,64] with corre-
sponding quality control procedures. We conducted the
CT at baseline on each participant to determine coronary
artery calcium and arterial stenoses. Agatston coronary cal-
cification scores, volume, volumetric scores, and mass for
the four main coronary arteries and cardiac valves were
Table 2 Cardiovascular assessment of PACE participants




and 12 Lead ECG
Recorded using standard 12 and
Frank orthogonal XYZ leads during a
minimum of 5 minutes at rest with a
1000 Hz sampling frequency and
high-pass filter 0.05 Hz and low pass
filter 350 Hz.
12 Lead ECG: Heart rate rhythm Sinus rhythm, tachy/bradycardia
PC ECG machine (Norav
Medical Ltd, Thornhill, ON,
Canada) and Marquette
ECG* (GE Medical Systems,
Milwaukee, WI)
Signal Averaged ECG: Ventricular
late potentials
Ventricular late potentials considered positive
with 2 or more criteria: (1) fQRSd >114 ms,
(2) LAS-40 > 38 ms, and (3) RMS-40 < 20 μV,
where fQRSd is total filtered QRS duration;
LAS-40 is duration of the low-amplitude sig-
nals (<40 mV) in the terminal portion; and
RMS-40 is root mean square voltage of the
last 40 ms.
Corrected QT interval QT variability
index (QTVI)
QTc > 0.44 QTVI > −0.5





gating with gantry rotation times
350–400 msec. Scans triggered by
electrocardiography signal at 70-80%
RR interval, near the end of diastole,
and before atrial contractions, to
minimize the effect of cardiac motion.
Conducted with IV visipaque contrast
if not contraindicated and metoprolol
if heart rate greater than 70 beat per
minute.
Left main (LM) Left anterior
descending (LAD) Left anterior
descending (LAD) Left circumflex
(LCX) Right coronary artery (RCA)
Coronary vessel stenosis defined as
significant narrowing (50% or more
diameter reduction) of the lumen.
Toshiba Aquilon 32
(Toshiba, Japan)
Coronary calcium score Valvular
calcium
Coronary calcium determined using
Agatston score. Valvular calcium is
measured.
Echocardiogram Conducted in a reclined position
with 4 chamber views and M mode
echocardiography to determine left
ventricular and atrial dimensions
Ejection fraction (EF) EF = (EDV-ESV / EDV) x100%
Toshiba Artida,
(Toshiba, Japan)
Aortic root pulmonary arterial
pressure
Aortic root normal parameters = 0.6-1.1Cm
tricuspid regurgitation pressures
LV mass index* LV mass = 0.8 (1.04 ([LVIDD + PWTD +
IVSTD]3- [LVIDD]3)) + 0.6 g
Pulse wave velocity Measures are performed supine after
5 minutes of rest using the right
carotid and right femoral arteries.
The operator captures 10 seconds of
stable waveform and repeats the
sequence using the femoral artery.
The computer generated aortic PWV
with a standard deviation is
reviewed.
Carotid-femoral pulse wave velocity
Sphygmocor PVx system
(Atcor Medical, Australia)
Pulse wave analysis Measures are performed supine after
5 minutes of rest using the right
radial artery (left radial artery if right
access is dialysis access present). The
operator captures 10 seconds of
stable waveform. The computer
generated quality indices and
operator index are reviewed.
Systolic central aortic pressure
Diastolic central aortic pressure




Ankle Brachial Index (ABI) Measures are performed after
5 minutes of rest in a supine
position and assessed by measuring
blood pressure bilaterally in the
brachial, dorsalis pedis and posterior
tibial arteries.
Right brachial pressure right
posterior tibial artery (PTA) right
dorsalis pedis artery (DPA) left
brachial pressure left posterior tibial
artery (PTA) left dorsalis pedis artery
(DPA)
Right ABI = Higher of the right ankle
pressures (PT or DP)/ Higher arm pressure
(right or left) Left ABI = Higher of the left
ankle pressures (PT or DP)/ Higher arm
pressure (right or left)
Doppler probe
*by Devereux formula; LVIDD = Left Ventricular Internal Diameter in Diastole, PWTD = Posterior Wall Thickness in Diastole, IVSTD = Interventricular Septum
Thickness in Diastole.
Parekh et al. BMC Nephrology  (2015) 16:63 Page 7 of 14calculated. Aortic or mitral valvular calcification was also
defined as present or not. Coronary artery stenosis was de-
fined as significant narrowing (50% or more diameterreduction) of the lumen of the four main coronary
branches: left main, left anterior descending, left circum-
flex, and right coronary artery, including side branches
Parekh et al. BMC Nephrology  (2015) 16:63 Page 8 of 14according to the AHA classification [75]. The effect-
ive radiation dose estimation for the entire study that
includes CT angiography and calcium measurement
was approximately 5–7 mSv (~0.7 rem). Prior to the
study, a beta-blocker, metoprolol, was given orally to
bring the heart rate to less than 65 beats per minute.
Based on protocol, trained cardiologists and radiolo-
gists independently read all CT images to assess for
both cardiac and non-cardiac pathologies and sub-
mitted a separate report of these findings within a
week [76].
Echocardiograms were conducted by three trained
echocardiographers at baseline on each participant to
determine LV stroke volume, LV ejection fraction,
and LV mass index with four chamber views and
standard calculations for LV mass. The M-mode by
the parasternal short axis view was used to estimate
LV mass, as the long axis view can result in im-
proper alignment and overestimate LV dimensions
and mass [77]. Additionally, we collected pulmonary
artery pressures based on flow at the tricuspid valve.
This was not always possible based on body habitus
and lack of regurgitation evident at the valve. All cardio-
vascular studies were centrally read at the Johns Hopkins
Cardiovascular Laboratory.
Aortic pulse wave velocity (PWV) measures were per-
formed supine after at least 5 minutes of rest using the
right carotid and right femoral arteries by four trained
research staff [78]. The operator captured 10 seconds of
stable carotid waveform and repeated the sequence using
the femoral artery. After the second waveform was cap-
tured, the computer generated an estimate of aortic
PWV with a standard deviation. If the standard devi-
ation was more than 15% of the PWV value, the study
was repeated. Pulse wave analysis was also measured
using tonometry of the right radial artery (and left if ar-
teriovenous fistula was present). Quality control was
assessed in real-time using quality indices and operator
index for each waveform generated. Additional internal
quality control included review of study procedures by
operator every 6 months to ensure adherence to the
protocol.
Ankle brachial index (ABI) was performed with the
patient resting for 5–10 minutes in a supine position
and assessed by measuring blood pressures with a
Doppler probe bilaterally in the brachial, dorsalis
pedis, and posterior tibial arteries. The right and left
ankle–brachial index values were determined by div-
iding the higher ankle pressure in each leg by the
higher arm pressure.
Adjudicated baseline comorbidities
Baseline comorbidity was assessed by the Charlson co-
morbidity index and was adjudicated by the PACEEndpoint Committee with two independent reviews and
a third final review. If a a consensus was not reached,
other members of the committee reviewed the chart and
a majority vote of the committee determined the final
cormorbidity. Assigned cause of ESRD was obtained
from medical record review, kidney biopsy records if
provided, and CMS-2728.
Adjudicated clinical cardiovascular events and outcomes
All clinical events from hospitalizations and emergency
room visits during follow-up used adjudication protocols
similar to the CRIC Study [63,64], except for arrhyth-
mias by ECG which were assessed annually during study
visits. All deaths are currently being adjudicated by the
PACE Endpoint Committee with two independent reviews
of deaths. If there is not a consensus, a third member of
the committee review the chart and a majority vote of the
committee determines the final cause of the death.
Cardiovascular events
We also obtained discharge summaries for all hospitali-
zations as reported by participants or dialysis unit. In
addition, surveillance of hospitals commonly fre-
quented by participants was conducted to minimize
missed emergency room visits, hospitalizations, or
deaths. Also, linkage to the United States Renal Data Sys-
tems (USRDS) in the future will allow for additional data
capture on healthcare utilization.
We define composite outcomes of cardiovascular dis-
ease (Table 3). Atherosclerotic disease is classified by
standardized definitions for myocardial infarction, cor-
onary revascularization procedures, stroke, carotid end-
arterectomy, congestive heart failure, and peripheral
vascular disease by amputation or peripheral surgical/
percutaneous. Clinical or symptomatic arrhythmic events
include treated atrial fibrillation/atrial flutter, heart
block or bradycardias, ventricular fibrillation or tachycar-
dia, and additional procedures for a pacemaker or defibril-
lator or electrocardioversion or ablation. Composite of
arrhythmic disease is: (1) atrial arrhythmias including
atrial fibrillation by annual ECGs and new arrhythmic
events such as treated atrial fibrillation by electrocar-
dioversion or ablation or rate control by pharmaco-
logical intervention, and death related to atrial
fibrillation [79,80]; and (2) ventricular-related arrhyth-
mias including ventricular tachycardia by annual ECGs,
SCD, hospitalized arrhythmias, and placement of im-
plantable defibrillators [81].
Mortality
From our regular contact with the dialysis unit, we
have been informed of a participant’s death. Once no-
tified of a participant’s death, we obtained the CMS
death notification form (CMS-2746). We also interviewed








Myocardial infarction Clinical symptoms Jaw pain or chest
Pain
ECG markers Major Q wave
ST elevation with
or without Q wave
Cardiac biomarkers Troponin I
CK-MB or CK total
Congestive heart
failure/Volume overload





Radiographic evidence Inspiratory crackles
S3 gallop























and supportive CT and
MRI evidence





















Table 3 Adjudicated hospitalization events in the PACE
study (Continued)
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last seen prior to death or the last hospitalization and
whether any symptoms preceded the event. All re-
cords from the hospitalization or emergency room
visit were also obtained. To ensure that death ascer-
tainment is complete, we searched the National Death
Index annually for persons lost to follow-up [82].
Sudden cardiac death
We used similar criteria for death classification adapted
from the HEMO and CRIC studies [83]. SCD was de-
fined as a sudden pulseless condition (collapse or syn-
cope) presumed to be due to an arrhythmia occurring
out of the hospital or in the emergency room in an
otherwise stable individual. In case of an unwitnessed
event, there was an evidence that the patient was seen in
a stable condition within the 24 hours preceding the
event (or since the last dialysis session). All events that
occurred during a hospitalization, or in nursing home,
or hospice were not classified as SCD. Deaths attributed
to coronary artery disease as similarly defined in the
Atherosclerosis Risk in Communities (ARIC) Study [84]
if the patients (1) have had a definite myocardial infarc-
tion within 4 weeks of death, or (2) have had chest pain
within 72 hours of death in cases of out-of-hospital
death or cardiac pain in cases of in-hospital death, or (3)
history of chronic ischemic heart disease such as myo-
cardial infarction, coronary insufficiency, or angina pec-
toris, or (4) the underlying cause of death in the death
certificate included ICD-10 code I20, I21, I22, I23, I24,
I25, I46, I51.6, I51.9, R99, J96, if there was no evidence
of a non-atherosclerotic or non-cardiac atherosclerotic
process that was the probable cause of death.
Biorepository
A biorepository consists of blood and toenail specimens
collected at baseline and annually therafter. The bio-
logical collections include DNA, RNA, serum, plasma,
whole blood, and buffy coat. Specimens were aliquoted
and stored at −80°C. We also used quality control sam-
ples to assess for laboratory variation with any testing.
Table 4 PACE study population and comparison to
incident US dialysis cohorts
Dialysis study PACE CDS* USRDS*
Time period 2009-2012 2005-2007 2008
Incident population, n 574 1646 110,175
African American 66% 28% 28.8%
Mean age, yrs 56 60 62.8
Younger age <65 years 73% 61.8% 52.8%
Diabetes 53% 52.6% 44.9%
Mean BMI, kg/m2 29.3 29.8 28.4
Male 54% 55.1% 57.6%





















*CDS-Comprehensive Dialysis Study 1646 completed phone interview;
USRDS- United States Renal Data Systems.
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The protocol described is approved by the Johns Hopkins
School of Medicine Institutional Review Board and
MedStar Institutional Review Board. The study was sup-
ported by the grant R01DK72367 from the National
Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) of the National Institutes of Health (NIH). Add-
itional support has been provided through the Doris Duke
Foundation and the National Kidney Foundation of
Maryland. The clinical study visit was supported by fund-
ing from UL1 RR 025005 from the National Center for
Research Resources (NCRR), a component of the NIH,
and NIH Roadmap for Medical Research.
Clinical characteristics of the PACE study population
We screened a total of 1736 individuals identified as in-
cident dialysis patients by dialysis staff of which, 943
(54.3%) met eligibility criteria. Those with either a pace-
maker (n = 89) or an automatic implanatable cardiover-
ter defibrillator (n = 70) at time of screening were
ineligible to participate in the study in addition to other
reasons such as nursing home residents, inability to con-
sent, history of recent cancer and history of peritoneal
dialysis or transplantation. A total of 574 participants
(61% of 943) were consented into the study with 402
completing the baseline cardiac evaluation. The median
follow-up time was 1.78 years (range 0–5.43) with 52
participants who underwent kidney transplantation, 25
who transferred to peritoneal dialysis, and 106 who died
as of July 31, 2014.
The PACE study population is predominantly younger
and comprised of a larger proportion of African Americans
than described in the national Comprehensive Dialysis
Study (CDS) or the USRDS (Table 4) [1,85]. In Table 5, the
baseline demographic and clinical characteristics are shown
for the study population enrolled. The baseline characteris-
tics of the cardiac measures, laboratory tests and medica-
tions are also provided for those who have completed the
initial study visit with the detailed cardiac evaluation.
Data safety monitoring board
We had an independent Data Safety Monitoring
Committee with three physicians in nephrology and
cardiology who reviewed any adverse events related
to study procedures twice a year. The Committee
reviewed events that occurred during the study visits or
from the study’s cardiac imaging procedures. Clinical read-
ings of the echocardiogram, CT angiography, and CT chest
over-reads were required even though they were
obtained for clinical research, as the discovery of inci-
dental findings may have necessitated the timely
reporting of critical results to the primary nephrolo-
gists, dialysis facilities, primary care physicians, and partic-
ipants [76]. Depending on the findings, we had instituteda protocol to report urgent findings that required inter-
vention to the nephrologist and participant.
Discussion
The PACE Study is unique compared to other dialysis
cohorts, as all participants are recruited within 6 months
of initiating chronic hemodilaysis. Ethnic disparities are
evident in survival on dialysis, and cardiovascular risk
among African Americans with ESRD has not been well-
studied. Morever, confounding by age-related disease
may lead to biased results. The PACE cohort is enriched
with African American participants and younger adults;
therefore, it is well poised to evaluate these noted ethnic
disparities and confounding. Additionally, the cohort has
comprehensive and detailed baseline cardiovascular
phenotyping and longitudinal electronic data for all out-
patient dialysis treatments. The PACE study has also
ascertained the important clinical endpoints of hospitali-
zations and adjudicated deaths. The biorepository of col-
lected specimens at baseline and follow-up will allow
future assessment of serologic or genetic markers associ-
ated with SCD or other outcomes.
Table 5 Baseline demographic and clinical characteristics
of all enrolled PACE participants (n = 574) and completed







Male, n (%) 319 (56) 233 (59)
African-American, n (%) 397 (69) 288 (72)
Age in years, mean ± SD 56 (13.5) 55 (13.2)
Education, % graduated high school 62 248 (63)
Employment, % employed 12 47 (12)
Marital status, % married 31 29
Dialysis characteristics
Three times a week dialysis, n (%) 566 (98.6) 397 (98.8)
Three to four hour dialysis session, n (%) 505 (88.0) 353 (87.8)
Polyflux membrane, n (%) 446 (77.7) 306 (86.4)
Arteriovenous fistula access, n (%) 163 (28.7) 122 (30.3)
Self reported
Smoking, % ever smoker 59 60
Body mass index kg/m2, mean ± SD 29.4 (7.9) 29.3 (7.8)
CVD, % diagnosed 44 45
CHF, % diagnosed 23 25
Diabetes, % diagnosed 54 55
Cardiovascular study visit
Systolic blood pressure mmHg, mean ± SD n/a 137 (25)
Diastolic blood pressure mmHg, mean ± SD n/a 75 (15)
Waist to hip ratio n/a 0.95 (0.08)
Frailty, % diagnosed n/a 40
Average literacy, mean n/a Grade 8
Cognitively impaired, % diagnosed n/a 14
Depression, % diagnosed n/a 17
Medications use
Betablocker, % n/a 58
ACEI/ARB, % n/a 44
Calcium channel blocker, % n/a 60
Statins, % n/a 52
Intradialytic labs
Ionized calcium mean ± SD. mmol/L n/a 1.15 (0.07)
Magnesium mean ± SD, mg/dL n/a 1.76 (0.24)
*Cardiovascular study visits were conducted at the Institute for Clinical and
Translational Research and the Cardiology Research Laboratory.
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and trials have often resulted in lower participation, the
need to extend recruitment time, or inclusion of prevalent
patients to achieve targets. Patients have significant
morbidity and mortality especially in the first
3 months on dialysis, hence the definition of chronicdialysis is defined as dialysis longer than 3 months
[1]. In recruiting the PACE study population, many
participants had hospitalizations or various clinical
visits (e.g. vascular access evaluation) that prevented
follow-up with the study visit for cardiovascular
evaluation. Nonetheless, recruitment of participants at
dialysis initiation is imperative as studying prevalent
patients brings an inherent survival bias to studies on
cardiovascular risk. In order to recruit our dialysis
cohort, we collaborated with outpatient dialysis units
throughout the Baltimore region. This collaborative
network and support from both community and aca-
demic nephrologists was vital to the development of
the PACE cohort and longitudinal follow-up. We de-
veloped a number of strategies to improve study par-
ticipation with paid transportation to and from the
study visit, phone call reminders, and renumeration
for each study visit attended.
Noninvasive cardiovascular imaging in studies
among dialysis patients is needed to understand sur-
rogate outcomes of cardiovascular disease and poten-
tially develop measures to be used in the clinical
setting. Conducting cardiovascular studies such as CT
angiography, however, requires more careful planning,
as imaging requires medication to lower heart rate
prior to studies, use of intravenous contrast, need for
appropriate screening for contrast reactions, concerns
of preserving residual kidney function, consideration
of radiation exposure, and lastly, appropriate proto-
cols for reporting urgent clinical and incidental find-
ings. These hidden burdens to the participant and study
team require significant planning and follow-up not typ-
ical in most observational studies. Moreover, reporting of
incidental findings to both participants and care providers
adds significant responsibility to nephrologist and study
team for reporting findings in a time sensitive manner, as
well as potentially increasing the need for further imaging
and work-up and increased worry to the participant. Re-
quirements by ethics boards for vigilant reporting of inci-
dentalomas does not take into account the lack of a
actionable plans for most findings and the concerns of
participants of unnecessary testing [76].
The overall rate of SCD in the U.S. dialysis population
is extremely high but understudied, thus limiting our
understanding of the pathogenesis leading to SCD. Stud-
ies such as PACE are needed to determine the incidence
of arrhythmias and SCD in persons on hemodialysis and
the association with cardiovascular and dialysis-related
risk factors. The results of the studies will provide essen-
tial information to ultimately prevent fatal arrhythmias
and prolong life.
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